You are here
ARBOR VITA CORPORATION
UEI: U5ASFV5Q36Y7
# of Employees: N/A
HUBZone Owned: No
Socially and Economically Disadvantaged: No
Woman Owned: No
Award Charts
Award Listing
-
Commercialization of the OncoE6TM Cervical Test for detection of HPV induced mali
Amount: $961,000.00DESCRIPTION (provided by applicant): Commercialization of the OncoE6TM Cervical Test for detection of HPV induced malignancy Cervical cancer is a major cause of the cancer-related mortality of women a ...
SBIRPhase II2013Department of Health and Human Services National Institutes of Health -
Development of an HPV-E6 Cervical Neoplasia Test for Use in Centralized Diagnosti
Amount: $296,989.00DESCRIPTION (provided by applicant): Cervical cancer is the leading cause of cancer-related death in women. It causes over 250,000 death world-wide / year, with 80% occurring in countries without sys ...
SBIRPhase I2012Department of Health and Human Services National Institutes of Health -
PDZ-targeted Therapeutics for Cervical Cancer
Amount: $208,622.00DESCRIPTION (provided by applicant): Oncogenic variants of human papilloma virus (HPV) have been correlated with cervical cancer at a frequency of gt 99%, and also cause penile, anal and head and nec ...
SBIRPhase I2010Department of Health and Human Services National Institutes of Health -
E6 Oncoprotein Based Rapid Test for Anal Neoplasia
Amount: $692,354.00DESCRIPTION (provided by applicant): The prevalence of anal pre-cancer and cancer have substantially increased during the past decades. This is especially true for HIV-positive men and women, and for ...
SBIRPhase I2010Department of Health and Human Services National Institutes of Health -
Development of an E6 based Rapid Strip Test Commercial Prototype for Cervical Can
Amount: $2,000,000.00DESCRIPTION (provided by applicant): Cervical cancer is a global health problem that continues to result in over 250,000 deaths a year, with 80% occurring in developing countries. Early detection of c ...
SBIRPhase II2009Department of Health and Human Services National Institutes of Health -
Translation of a Novel Stroke Drug Administration
Amount: $1,543,800.00DESCRIPTION (provided by applicant): Stroke is a major cause of morbidity in the United States, affecting over 600,000 people annually. The only therapeutics currently available for the treatment of s ...
SBIRPhase II2009Department of Health and Human Services National Institutes of Health -
A Novel Diagnostic Assay for Oncogenic Human Papillomaviruses
Amount: $875,698.00DESCRIPTION (provided by applicant): Arbor Vita Corporation (AVC) has developed a novel cervical cancer diagnostic based on an understanding of the biology of human papillomavirus (HPV). HPV infection ...
SBIRPhase II2006Department of Health and Human Services National Institutes of Health -
Rapid Strip Test for Cervical Cancer via HPV-E6 Detection
Amount: $597,497.00DESCRIPTION (provided by applicant): Cervical cancer is a global health problem that continues to result in over 200,000 deaths a year and has one of the worst survival rates following diagnosis. Earl ...
SBIRPhase I2006Department of Health and Human Services National Institutes of Health -
A Novel Drug To Reduce Neronal Damage Following Stroke
Amount: $197,624.00DESCRIPTION (PROVIDED BY APPLICANT): Arbor Vita proposes to determine the selectivity profiles of NMDA Receptors for PDZ domains and to identify selective inhibitors for use in reducing neuronal damag ...
SBIRPhase I2005Department of Health and Human Services National Institutes of Health -
Prevention and Treatment of Cervical Cancer
Amount: $200,186.00DESCRIPTION (provided by applicant): Arbor Vita proposes to validate the interactions of oncogenic E6 variants with a specific cellular protein family as a target for therapeutic intervention in Human ...
SBIRPhase I2003Department of Health and Human Services National Institutes of Health
